Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | nuclear factor, erythroid 2-like 2 | Starlite/ChEMBL | No references |
Homo sapiens | jun proto-oncogene | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Echinococcus granulosus | Basic leucine zipper bZIP transcription factor | Get druggable targets OG5_131442 | All targets in OG5_131442 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription factor | Get druggable targets OG5_131442 | All targets in OG5_131442 |
Echinococcus multilocularis | jun protein | Get druggable targets OG5_131442 | All targets in OG5_131442 |
Echinococcus granulosus | jun protein | Get druggable targets OG5_131442 | All targets in OG5_131442 |
Brugia malayi | bZIP transcription factor family protein | Get druggable targets OG5_131442 | All targets in OG5_131442 |
Loa Loa (eye worm) | hypothetical protein | Get druggable targets OG5_131442 | All targets in OG5_131442 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | jun protein | 0.0101 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0099 | 0.8724 | 0.5 |
Onchocerca volvulus | 0.008 | 0 | 0.5 | |
Schistosoma mansoni | hypothetical protein | 0.0082 | 0.1276 | 0.5 |
Echinococcus granulosus | jun protein | 0.0101 | 1 | 0.5 |
Schistosoma mansoni | jun-related protein | 0.0082 | 0.1276 | 0.5 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription factor | 0.0101 | 1 | 0.5 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription factor | 0.0101 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 15.6211 uM | PubChem BioAssay: Tox21. qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 19.833 uM | PubChem BioAssay: Tox21. qHTS assay to identify small molecule agonists of the AP-1 signaling pathway. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 24.9682 uM | PubChem BioAssay: Tox21. qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 24.9682 uM | PubChem BioAssay: Tox21. qHTS assay for small molecule activators of the heat shock response signaling pathway. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 55.4259 uM | PubChem BioAssay: Tox21. qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 55.8969 uM | PubChem BioAssay: Tox21. qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 55.8969 uM | PubChem BioAssay: Tox21. qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 55.8969 uM | PubChem BioAssay: Tox21. qHTS assay to identify small molecule agonists of the NFkB signaling pathway. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 62.7173 uM | PubChem BioAssay: Tox21. qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway. (Class of assay: confirmatory) | ChEMBL. | No reference |
pTD50 (functional) | = 2.635 | Anticarcinogenic activity in rat assessed as induction of tumors per day | ChEMBL. | 18295489 |
TD50 (functional) | = 431.796 umol/Kg | Anticarcinogenic activity in rat assessed as induction of tumors per day | ChEMBL. | 18295489 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.